Hepatobiliary division of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Ann Surg Oncol. 2021 Oct;28(11):6767-6768. doi: 10.1245/s10434-021-09702-8. Epub 2021 Feb 15.
Revision surgery with or without chemotherapy in the neoadjuvant or adjuvant setting remains the standard treatment for incidental gallbladder cancers (iGBCs). Over the years, researchers have retrospectively analyzed the surgical audits and tried to establish the perceived benefit and optimal timing for revision surgery. Patkar and colleagues have analyzed the outcomes for 517 patients with iGBC, concluding that there is no optimal timing for performing a revision surgery after initial cholecystectomy. Revision surgery is essentially the most accurate staging procedure and should be offered to patients at any time of presentation if they remain non-metastatic. Timely initiation of chemotherapy is the key to improving the outcomes for patients with this otherwise inherently aggressive disease.
对于偶发胆囊癌(iGBC),新辅助或辅助放化疗后行修正手术仍然是标准治疗方法。多年来,研究人员回顾性分析了手术记录并试图确定修正手术的获益和最佳时机。Patkar 及其同事分析了 517 例 iGBC 患者的结果,得出结论:初始胆囊切除术后,行修正手术的最佳时机并不明确。修正手术本质上是最准确的分期手术,如果患者仍无转移,应在任何时候向其提供修正手术。及时开始化疗是改善此类侵袭性固有疾病患者预后的关键。